Position in LLY
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$1,278,388,323
New position
Shares Held
1,389,900
first reported quarter
Ownership
0.148%
of shares outstanding
% of Portfolio
1.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026VANGUARD ASSET MANAGEMENT, Ltd holds $8,725,015,642 across 11 Drug Manufacturers - General names. LLY ranks #2 (14.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
18,535,315 | $3,655,534,824 | |
| 2 | LLY |
ELI LILLY & Co
This page
|
1,389,900 | $1,278,388,323 | |
| 3 | JNJ |
Johnson & Johnson
|
4,370,041 | $1,068,212,822 | |
| 4 | ABBV |
AbbVie Inc.
|
3,559,819 | $774,225,034 | |
| 5 | MRK |
Merck & Co., Inc.
|
5,003,623 | $601,885,810 | |
| 6 | AMGN |
Amgen Inc
|
1,083,147 | $381,105,271 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
2,503,751 | $348,947,776 | |
| 8 | PFE |
Pfizer Inc
|
11,424,753 | $320,807,064 |
All Filings in LLY
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,278,388,323 | 1,389,900 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||